Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682041 | 1.00 | FUCA1 (0.49) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL10067586 | 1.00 | FUCA1 (0.49) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL16033409 | 0.80 | FUCA1 (0.43) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL16033411 | 0.80 | FUCA1 (0.43) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL16033408 | 0.80 | FUCA1 (0.43) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL16759827 | 0.80 | FUCA1 (0.64) | FUCA1ALDH1A1S1PR1S1PR5ACHE | |
| SCHEMBL16775256 | 0.80 | FUCA1 (0.64) | FUCA1ALDH1A1S1PR1S1PR5ACHE | |
| SCHEMBL4780450 | 0.77 | BPTF (0.43) | KDM4EALDH1A1MAPTHTTSIGMAR1 | |
| SCHEMBL19271008 | 0.77 | BCHE (0.40) | FUCA1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL8266080 | 0.76 | ACHE (0.45) | FUCA1KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-3147283-B1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR XA INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY LTD (CN) | 2022-08-17 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3147283-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | North China Pharmaceutical Company., Ltd. (CN) | 2017-03-29 | — | — | EP | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1881977-A1 | HISTONE DEACETYLASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-0629189-B1 | PREPARATION OF INTERMEDIATES IN THE SYNTHESIS OF QUINOLINE ANTIBIOTICS | PFIZER (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0740667-A1 | PROCESS AND INTERMEDIATES FOR PREPARING NAPHTHYRIDONECARBOXYLIC ACID SALTS | PFIZER INC. (US) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019361-A1 | PROCESS AND INTERMEDIATES FOR PREPARING NAPHTHYRIDONECARBOXYLIC ACID SALTS | PFIZER INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| US-5298629-A | Intermediates in the synthesis of quinoline antibiotics | PFIZER INC. (US) | 1994-03-29 | — | — | US | disclosed |
| US-5256791-A | Preparation of intermediates in the synthesis of quinoline antibiotics | PFIZER INC. (US) | 1993-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | FUCA1 2256/4885KDM4E 1648/4885ALDH1A1 1320/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | FUCA1 2256/4885KDM4E 1648/4885ALDH1A1 1320/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | FUCA1 892/4885KDM4E 1233/4885ALDH1A1 2302/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | FUCA1 2256/4885KDM4E 1648/4885ALDH1A1 1320/4885 |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | FUCA1 3035/4885KDM4E 281/4885ALDH1A1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.